abstract |
Bergamottin, principle compound in grapefruit juice responsible for inhibition of p450 3a4, the predominant p450 enzyme in the intestine, is coadministered with a compound having low bioavailability to a patient to increase oral bioavailability of the compound and pharmaceutical compositions of the same, as well as a method of isolating bg from grapefruit juice. |